XORTX Therapeutics (XRTX) Beginning Cash Balance (2021 - 2026)

XORTX Therapeutics' Beginning Cash Balance history runs 6 years deep, the most recent figure standing at $864514.0 for Q1 2026.

• Quarterly Beginning Cash Balance fell 65.05% year-over-year to $864514.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $864514.0 (down 65.05% YoY) and the FY2025 annual result came in at $2.5 million, down 28.25% from the prior year.
• Beginning Cash Balance was $864514.0 for Q1 2026 at XORTX Therapeutics, down from $2.5 million in the prior quarter.
• Across five years, Beginning Cash Balance topped out at $14.9 million in Q1 2022 and bottomed at $864514.0 in Q1 2026.
• A 5-year average of $6.4 million and a median of $3.4 million in 2024 frame the typical range for Beginning Cash Balance.
• Annual changes were most pronounced in 2022 — Beginning Cash Balance soared 10897.99% — and 2024, when it plunged 66.96%.
• XORTX Therapeutics' Beginning Cash Balance stood at $14.9 million in 2022, then decreased by 29.89% to $10.4 million in 2023, then plunged by 66.96% to $3.4 million in 2024, then fell by 28.25% to $2.5 million in 2025, then plunged by 65.05% to $864514.0 in 2026.
• Business Quant data shows XRTX's Beginning Cash Balance at $864514.0 in Q1 2026, $2.5 million in Q1 2025, and $3.4 million in Q1 2024.